CR Double-Crane gets approval for sugammadex injection

China Resources Double-Crane Pharmaceutical (SSE:600062) announced that it has received approval from China's National Medical Products Administration (NMPA) for a supplementary application regarding its Sugammadex Sodium Injection. This approval adds a new specification of 5ml:500mg (based on the total amount of sugammadex sodium active substance and mono-hydroxy sugammadex sodium active substance) to the existing 2ml:200mg specification. The company expects this expansion to boost its market competitiveness. Sugammadex Sodium Injection is used to reverse neuromuscular blockade induced by rocuronium or vecuronium in adults and is sold under the brand name Bridion by Merck Sharp & Dohme (MSD) globally. According to global pharmaceutical sales data, the global sales of Sugammadex Sodium Injection in 2023 were USD 1.89 billion.